Crossmark

Efficacy and Safety of Mirogabalin in Patients with Neuropathic Pain Due to Cervical Spondylotic Radiculopathy: Miro-Cens, A Randomized, Controlled, Interventional Study

Crossref DOI link: https://doi.org/10.1007/s40122-025-00722-w

Published Online: 2025-04-12

Published Print: 2025-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hirai, Takashi

Okawa, Atsushi

Takahashi, Hiroshi

Shiosakai, Kazuhito

Yoshii, Toshitaka

,
Funding

Funding for this research was provided by:

Daiichi-Sankyo
License Information

Text and Data Mining valid from 2025-04-12

Version of Record valid from 2025-04-12
More Information

Article History

Received: 29 November 2024

Accepted: 4 March 2025

First Online: 12 April 2025

Change Date: 26 December 2025

Change Type: Update

Change Details: The original online version of this article was revised to correct the supplementary file.

Declarations

:

: Takashi Hirai had no conflict of interest to be declared. Atsushi Okawa and Toshitaka Yoshii received lecture fees from Daiichi Sankyo Co., Ltd. Hiroshi Takahashi and Kazuhito Shiosakai are employees of Daiichi Sankyo Co., Ltd.

: The study was approved by Tokyo Medical and Dental University Certified Review Board (current name, Institution of Science Tokyo) (CRB No. 3240003). The study was conducted in accordance with the Clinical Research Act in Japan, and the ethical principles, clinical research laws, and relevant notifications stipulated in the Declaration of Helsinki (as revised in 2013). This study was registered in the Japan Registry of Clinical Trials under the identifier jRCTs031210629. All patients provided informed consent to participate in the study.

Document is current

Any future updates will be listed below